Investment Highlights

DepoVax™ is a novel vaccine adjuvanting technology platform
  • Antigen presentation with DepoVax produces a strong, high quality and sustained immune response
  • Safe and well tolerated
  • Well-developed technology with a breadth of internal and external development programs
 
Dynamic multi-pronged growth strategy
  • Leverage DepoVax as a potent and flexible product-generating platform
  • Internally advance therapeutic cancer  vaccine candidates in development
  • Capture upside through collaborative and partnered programs in infectious diseases, addiction medicine and animal health
 
Clinical-stage therapeutic cancer vaccines: DPX-0907 and DPX-Survivac
  • Successful Phase I clinical trial of DPX-0907 completed in U.S.; data presented at 2012 ASCO conference and published in peer-reviewed Journal of Translational Medicine
  • Positive interim data from ongoing Phase I study of DPX-Suvivac in U.S. and Canada; all patients treated to date with vaccine produced targeted, dose-related immune responses
 
Broad infectious diseases vaccine pipeline
  • Key programs advancing in malaria, respiratory syncytial virus (RSV) and anthrax
 
Key collaborations progressing across broad range of vaccine applications
  • Next generation bio-defence vaccines through NIH supported studies
  • Positive preliminary preclinical study results for anti-cocaine vaccine in tandem with Weill Cornell Medical College
  • Vaccines against infectious diseases in collaboration with Dalhousie Infectious Disease Research Alliance (DIDRA)
 
Multiple partnerships leveraging DepoVax platform in animal health
  • Zoetis (formerly Pfizer Animal Health) developing vaccines for livestock applications
  • World leading animal health company developing next generation companion animal vaccines
 
Proprietary commercial-scale vaccine manufacturing capability 
 
 
Strong IP position with patents issued in the US, EU and Asia